# Meta-Reflection

## Executive Summary
Question about Zepbound Q4 2025 global revenue in millions USD, resolving on Feb 4, 2026 when Eli Lilly reports earnings. My central estimate is ~$4,000M with a fairly wide distribution reflecting uncertainty about sequential growth and international contribution. Confidence is moderate-to-high given the established growth trajectory and near-term resolution.

## Research Audit
- **Most useful searches**: Eli Lilly Q3 2025 earnings release (gave exact quarterly data), Statista revenue table (gave all historical quarters), Barchart Q4 2025 preview (consensus EPS)
- **Less useful**: Searches for Q4-specific Zepbound analyst consensus - couldn't find the exact product-level estimate
- **Gap**: I couldn't find the current Wall Street consensus for Q4 2025 Zepbound specifically. The Barchart article gave total EPS consensus ($7.47) but not product-level revenue breakdowns in the snippets.

## Reasoning Quality Check

*Strongest evidence FOR my forecast (~$4,000M median):*
1. Q3 2025 was $3,588M and growth has been steadily increasing YoY
2. Q4 seasonality historically positive for obesity drugs (year-end insurance)
3. No negative pre-announcement signals in-line or better performance
4. Japan launch in April 2025 adds incremental international revenue

*Strongest argument AGAINST:*
- Sequential growth decelerated sharply (Q2→Q3 was only +6.1%)
- Price cuts through LillyDirect could reduce revenue per unit
- The distribution could be too wide or too narrow given Q4 already happened

*Calibration:*
- This is a measurement question with near-term resolution (Feb 4)
- The actual number exists already - uncertainty is about what it is, not what will happen
- 80% CI roughly $3,550-$4,500M seems reasonable

## Subagent Decision
Did not use subagents - this was a relatively straightforward data-gathering exercise where sequential searches informed next steps. The question is well-defined and the research approach was linear.

## Tool Effectiveness
- search_exa: Very effective for finding earnings releases and financial data
- web_search: Helpful complement but often returned same results
- execute_code: Good for quick calculations
- WebFetch: Failed on barchart.com (web.archive.org redirect issue)

## Process Feedback
- The prompt guidance on measurement questions was relevant
- "Nothing Ever Happens" doesn't strongly apply since this is a measurement question
- Would have been helpful to have access to financial terminal data (Bloomberg/FactSet consensus)

## Calibration Tracking
- 80% CI: [$3,550M, $4,500M]
- Confidence: 70% that actual falls within my 80% CI
- Key update triggers: any Lilly pre-announcement in next 10 days
---

## Programmatic Metrics

*Auto-generated - do not edit manually*

- **Post ID**: 41747
- **Question ID**: 41487
- **Session Duration**: 320.1s (5.3 min)
- **Cost**: $5.0825
- **Tokens**: 15,208 total (54 in, 15,154 out)
  - Cache: 1,343,493 read, 102,928 created
- **Log File**: `logs/41747_20260206_221043/20260206_221044.log`

### Tool Calls

- **Total**: 27 calls
- **Errors**: 1 (3.7%)

| Tool | Calls | Errors | Avg Time |
|------|-------|--------|----------|
| execute_code | 2 | 0 | 145ms |
| get_metaculus_questions | 1 | 1 ⚠️ | 5185ms |
| notes | 2 | 0 | 1ms |
| search_exa | 17 | 0 | 2049ms |
| web_search | 5 | 0 | 1904ms |

### Sources Consulted

- Eli Lilly Q4 2025 earnings Zepbound revenue results
- Zepbound Q4 2025 sales revenue analyst estimates forecast
- Eli Lilly Q3 2025 Zepbound revenue sales results quarterly
- Zepbound Q4 2025 revenue analyst consensus estimate Wall Street expectations
- Eli Lilly earnings date Q4 2025 report when
- Eli Lilly Q4 2025 fourth quarter earnings report date January February 2026
- "Zepbound" Q4 2025 analyst estimate consensus revenue billion
- Zepbound international launch outside US global sales 2025
- Eli Lilly LLY Q4 2025 earnings preview Zepbound estimate Wall Street analyst ...
- Eli Lilly Zepbound Q4 2025 revenue estimate forecast $4 billion analyst preview
- Eli Lilly 2025 full year Zepbound revenue total annual estimate guidance
- Eli Lilly Zepbound Q4 2025 earnings preview analyst estimate $4 billion reven...
- Eli Lilly Q4 2025 earnings preview tirzepatide Zepbound sales expectations
- Eli Lilly Q4 2025 fourth quarter results preview Zepbound expectations foreca...
- https://www.barchart.com/story/news/37015541/what-to-expect-from-eli-lillys-q...
- barchart "Q4 2025" "Eli Lilly" Zepbound earnings report expect analyst consensus
- https://www.barchart.com/story/news/37015541/what-to-expect-from-eli-lillys-q...
- site:barchart.com "Q4 2025" "Eli Lilly" OR "LLY" Zepbound revenue estimate ea...
- Eli Lilly LLY Q4 2025 consensus revenue estimate $18 billion $17 billion Zepb...